Leading the Way in Life Science Technologies

GEN Exclusives

More »

November 15, Vol. 31, No. 20

  • Feature Articles

    • Flow Cytometry Shifting Gears
    • Kathy Liszewski
    • Although established more than 30 years ago, the field of flow cytometry continues to grow and advance It remains an indispensable tool for clinicians and researchers The “Northwest Regional Cytometry” meeting held earlier this year focused on cytometry data: mining, ... more »
    • GEN's 30th Anniversary: Molecular Diagnostics
    • In this issue’s “Biomarket Trends” column, Frost & Sullivan analyst Jonathan Witonsky notes that revenues from worldwide sales of molecular diagnostics were estimated to reach $4 billion last year and to rise to $6 billion by 2014 based on a ... more »
    • Microfluidics Making Bigger Impression
    • Vicki Glaser
    • Microfluidics technology development is entering a new phase, according to Andreas Manz, PhD, head of research at the Korea Institute of Science and Technology, Saarbrücken, Germany Now that the initial patents covering the fundamental technology have expired, companies can more ... more »
  • Columns

    • Samsung Stakes Out Biopharma Position
    • Carol Potera
    • Samsung, the South Korean company best known to Americans for televisions and other electronic equipment, is branching out to make biopharmaceuticals In May, ground was broken for Samsung Biologics located in Incheon, South Korea; full-scale operation is expected to start ... more »
    • Infectious Disease Molecular Diagnostics
    • Jonathan Witonsky
    • Molecular diagnostics are well-established in clinical medicine Nonetheless, the markets for these tests remain one of the most attractive growth opportunities in the in vitro diagnostics industry Approximately 600 hospital laboratories and 200 independent laboratories perform high-volume testing that necessitates ... more »
  • Tutorials

    • Enhanced Albumin Fusion Technology
    • Jason Cameron
    • The development of efficacious protein-based therapeutics is often hindered because many exhibit a short plasma half-life As a result, technologies addressing the extension of protein half-life are attracting considerable attention within the pharmaceutical industry... more »